Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 865 2352511, +7 865 2353229.


Comparative analysis of activity of cytochrome isoenzyme P450 C YP2C9 in elderly and senile patients and with that in healthy volunteers of the first period of middle age

[Internal diseases]
Dmitry Sychev; Sergey Bordovsky; Vladislav Nikulin; Natalia Polshina; Georgiy Anikin; Kristina Danilina; Valeriy Smirnov;

At the first phase of the research the evaluation of the activity of cytochrome CYP2C9 in 18 elderly and geriatric patients was carried out, mean age of the patients was 71.6±9.6 years. At the second phase the efficiency and safety of losartan trial in 18 healthy volunteers of the first period of mature age 26.3±3.5 years was evaluated. To evaluate the activity of isoenzyme of cytochrome P450 CYP2C9 the determination of the concentration of active metabolite of Losartan E-3174 in the urine to the concentration of losartan was used. The concentration ratio E-3174 to losartan in elderly and senile patients was 1.84±0.15, in healthy young volunteers – 3.28±0.77. A statistically significant metabolic E-3174/losartan ratio decrease in elderly and senile patients was demonstrated, which indicates about the decreased activity of CYP2C9 in that age group.


1. Belousov Y., Leonova M. Osobennosti primeneniya lekarstv v geriatricheskoy praktike. Farmateka. 2008;8:13–19.
2. Denisova T., Malinova L. Klinicheskaya gerontologiya: Izbrannye lektsii. 2008.
3. George M., Shewade D. G., Kumar S. V., Adithan C. Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug. Indian Journal of Pharmacology. 2012;44(4):485–488. doi:10.4103/0253-7613.99314
4. Jetter A., Kinzig-Schippers M., Skott A., Lazar A., Tomalik-Scharte D. [et al.] Cytochrome P 450 2C9 phenotyping using low-dose tolbutamide. European Journal of Clinical Pharmacology. 2004;60(3):165–171. doi:10.1007/s00228-004-0754-z
5. Joy M., Dornbrook-Lavender K., Blaisdell J., Hilliard T., Boyette T. [et al.] CYP2C9 genotype and pharmacodynamics responses to losartan in patients with primary and secondary kidney diseases. European Journal of Clinical Pharmacology. 2009;65(9):947–953. doi: 10.1007/s00228-009-0707-7
6. Klotz U. The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs. Clinical Pharmacokinetics. 2007;46(4):271–279. doi: 10.2165/00003088-200746040-00001
7. Osadchikh A., Puzin S., Lavrova D. Problemy invalidnosti v Rossii. Sostoyaniye i perspektivy. 2002.
8. Page C., Curtis M., Walker M. Pharmacology: a clinical approach. 2012.
9. Scordo M., Pengo V., Spina E., Dahl M. L., Gusella M. [et al.] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clinical Pharmacology & Therapeutics. 2002;72(6):702–710. doi: 10.1067/mcp.2002.129321
10. Shi S., Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. European Journal of Clinical Pharmacology. 2008;64(3):233–252. doi: 10.1007/s00228-007-0400-7
11. Sychev D. Rekomendatsii dlya farmatsevticheskikh kompany po izucheniyu biotransformatsii i transporterov novykh lekarstvennykh sredstv: dizayn issledovany, analiz dannykh i vneseniye informatsii v instruktsii po primeneniyu. 2009. Available at: http://www.regmed. ru/Content/Doc.aspx?id=26a9128c-ee32-4469-9c64-5c666339049e
12. Tanaka. In vivo age-related changes in hepatic drugoxidizing capacity in humans. Journal of Clinical Pharmacy and Therapeutics. 1998;23(4):247–255. doi: 10.1046/j.1365-2710.1998.00164.x

Keywords: drug therapy, drug side effects, CYP2C9 isoform, losartan, elderly people

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy